SCHEMBL20575445

SCHEMBL20575445

CC(NC(=O)C(Cc1ccc(-c2ccccc2)cc1)CP(=O)(O)C(C)N)C(=O)OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MME P08473 3/20 0.77
ANPEP P15144 2/20 0.77
ECE1 P42892 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6929404 0.95 MME (0.71) MMEANPEPECE1
SCHEMBL20526392 0.91 MME (0.64) MMEANPEPECE1
SCHEMBL20575159 0.91 MME (0.79) MMEANPEP
SCHEMBL12596644 0.91 MME (0.79) MMEANPEP
SCHEMBL20526400 0.91 MME (0.82) MMEANPEP
SCHEMBL28500639 0.88 MME (0.60) MMEANPEPECE1
SCHEMBL1764418 0.87 MME (1.00) MMEANPEP
SCHEMBL4992398 0.87 MME (1.00) MMEANPEP
SCHEMBL4992386 0.87 MME (1.00) MMEANPEP
SCHEMBL20526397 0.87 MME (1.00) MMEANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3592361-B1 AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION IACTA PHARMACEUTICALS INC (PR) 2023-09-13 EP claimed
US-10688113-B2 Methods of treating eye pain with aminophosphinic derivatives PHARMALEADS (FR) 2020-06-23 US claimed
US-20190167701-A1 Methods of Treating Eye Pain With Aminophosphinic Derivatives PHARMALEADS (FR) 2019-06-06 US claimed
US-20180344753-A1 AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN PHARMALEADS (FR) 2018-12-06 US claimed
EP-3592361-B1 AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING OCULAR INFLAMMATION IACTA PHARMACEUTICALS INC (PR) 2023-09-13 EP disclosed
US-10688113-B2 Methods of treating eye pain with aminophosphinic derivatives PHARMALEADS (FR) 2020-06-23 US disclosed
US-20190167701-A1 Methods of Treating Eye Pain With Aminophosphinic Derivatives PHARMALEADS (FR) 2019-06-06 US disclosed
US-20180344753-A1 AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN PHARMALEADS (FR) 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190167701-A1 Methods of Treating Eye Pain With Aminophosphinic Derivatives P2RX7, HRH3, P2RX6 MME 3364/4885ANPEP 1779/4885ECE1 2402/4885
US-10688113-B2 Methods of treating eye pain with aminophosphinic derivatives P2RX7, HRH3, P2RX6 MME 3364/4885ANPEP 1779/4885ECE1 2402/4885
US-20180344753-A1 AMINOPHOSPHINIC DERIVATIVES FOR PREVENTING AND TREATING EYE PAIN P2RX7, P2RY6, HRH3 MME 3636/4885ANPEP 973/4885ECE1 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.